Cargando…

Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure

Detalles Bibliográficos
Autores principales:	Santema, Bernadet T., Chan, Michelle M. Y., Tromp, Jasper, Dokter, Martin, van der Wal, Haye H., Emmens, Johanna E., Takens, Janny, Samani, Nilesh J., Ng, Leong L., Lang, Chim C., van der Meer, Peter, ter Maaten, Jozine M., Damman, Kevin, Dickstein, Kenneth, Cleland, John G., Zannad, Faiez, Anker, Stefan D., Metra, Marco, van der Harst, Pim, de Boer, Rudolf A., van Veldhuisen, Dirk J., Rienstra, Michiel, Lam, Carolyn S. P., Voors, Adriaan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318930/ https://www.ncbi.nlm.nih.gov/pubmed/33141252 http://dx.doi.org/10.1007/s00392-020-01762-2

Ejemplares similares

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
por: Santema, Bernadet T., et al.
Publicado: (2019)

Pathophysiological pathways in patients with heart failure and atrial fibrillation( )
por: Santema, Bernadet T, et al.
Publicado: (2021)

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation
por: Mordi, Ify R., et al.
Publicado: (2019)

Albuminuria as a marker of systemic congestion in patients with heart failure
por: Boorsma, Eva M, et al.
Publicado: (2022)

Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure
por: Boorsma, Eva M., et al.
Publicado: (2021)

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors
por: Sama, Iziah E, et al.
Publicado: (2020)

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
por: ter Maaten, Jozine M., et al.
Publicado: (2020)

The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure
por: Pandhi, Paloma, et al.
Publicado: (2021)

Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire
por: Ravera, Alice, et al.
Publicado: (2021)

A network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic heart failure
por: Sama, Iziah E., et al.
Publicado: (2020)

Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2020)

Clinical implications of low estimated protein intake in patients with heart failure
por: Streng, Koen W., et al.
Publicado: (2022)

Genetic risk and atrial fibrillation in patients with heart failure
por: Kloosterman, Mariëlle, et al.
Publicado: (2020)

Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients? Reply
por: Damman, Kevin, et al.
Publicado: (2020)

Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure
por: van der Wal, Haye H., et al.
Publicado: (2020)

Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) trial
por: ter Maaten, Jozine M., et al.
Publicado: (2022)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial
por: ter Maaten, Jozine M., et al.
Publicado: (2023)

Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use
por: van der Wal, Haye H, et al.
Publicado: (2019)

Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2021)

Clinical importance of urinary sodium excretion in acute heart failure
por: Damman, Kevin, et al.
Publicado: (2020)

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020)

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment
por: Nauta, Jan F., et al.
Publicado: (2019)

The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach
por: Hoes, Martijn F., et al.
Publicado: (2019)

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF
por: Pagnesi, Matteo, et al.
Publicado: (2021)

Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure
por: de Koning, Marie-Sophie L. Y., et al.
Publicado: (2023)

Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF
por: Markousis-Mavrogenis, George, et al.
Publicado: (2021)

Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates
por: Grote Beverborg, Niels, et al.
Publicado: (2015)

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure
por: Ceelen, Daan, et al.
Publicado: (2022)

Sexual dimorphism in selenium deficiency is associated with metabolic syndrome and prevalence of heart disease
por: Weening, Eerde H., et al.
Publicado: (2023)

Statins in the Treatment of Chronic Heart Failure: A Systematic Review
por: van der Harst, Pim, et al.
Publicado: (2006)

A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure
por: Linssen, G. C. M., et al.
Publicado: (2018)

Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence
por: Bracun, Valentina, et al.
Publicado: (2022)

Impaired High‐Density Lipoprotein Function in Patients With Heart Failure
por: Emmens, Johanna E., et al.
Publicado: (2021)

Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure
por: Pagnesi, Matteo, et al.
Publicado: (2022)

Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
por: Inciardi, Riccardo M., et al.
Publicado: (2022)

Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease
por: Emmens, Johanna E., et al.
Publicado: (2021)

Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure
por: Markousis-Mavrogenis, George, et al.
Publicado: (2023)

Preoperative cardiac screening using NT-proBNP in obese patients 50 years and older undergoing bariatric surgery: a study of 310 consecutive patients()
por: van Veldhuisen, Sophie L., et al.
Publicado: (2021)

Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study
por: Alnuwaysir, Ridha I.S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fahd9mrootgt8aii56q1ve3ere